Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 156 entries already.

Entries by jeremiah@devisedesigns.com

Neurology

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis

Mann et al • 2022 • European Network to Cure ALS (ENCALS)

February 3, 2023
Hypercortisolism (Cushing syndrome)

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome

Moritis et al • 2022 • European Congress of Endocrinology

February 2, 2023
Hypercortisolism (Cushing syndrome)

Mifepristone Use in Hypercortisolism from an Unknown Source: A Case Study

Brown et al • 2022 • American Association of Clinical Endocrinology (AACE) Annual Meeting

February 1, 2023
Hypercortisolism (Cushing syndrome)

When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis

Aresta et al • 2021 • Endocr Pract.

January 30, 2023
Hypercortisolism (Cushing syndrome)

Hidden hypercortisolism: a too frequently neglected clinical condition

Giovanelli et al • 2021 • J Endocrinol Invest.

January 29, 2023
Metabolism

Miricorilant, a selective GR modulator, induced a rapid and significant reduction in liver fat content in a randomized, placebo-controlled phase 2a study in patients with nonalcoholic steatohepatitis

Kowdley et al • 2021 • The Liver Meeting 2021 (American Association for the Study of Liver Diseases)

January 28, 2023
Oncology

Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study

Lorusso et al. • 2021 • European Society for Medical Oncology (ESMO) Congress 2021

January 27, 2023
Oncology

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

Greenstein et al. • 2021 • Oncotarget . 2021 Jun 22;12(13):1243-1255. doi: 10.18632/oncotarget.27989.

January 26, 2023
Oncology

Adrenal tumors provide insight into the role of cortisol in NK cell activity

Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.

January 25, 2023
Metabolism

Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study

Hunt et al • 2021 • Journal of Clinical Psychopharmacology: August 6, 2021

January 24, 2023
Page 7 of 16«‹56789›»

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top